Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

Clinical trial NCT07185373 · RECRUITING

Trial details

NCT number: NCT07185373
Sponsor: Huashan Hospital
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma

Start date: 2025-10-01
Primary completion: 2028-09-30
Enrollment: 215

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.